scholarly journals Delay in seeking treatment before emergent heart failure readmission and its association with clinical phenotype

2020 ◽  
Vol 8 (1) ◽  
Author(s):  
Makoto Takei ◽  
Kazumasa Harada ◽  
Yasuyuki Shiraishi ◽  
Junya Matsuda ◽  
Yoichi Iwasaki ◽  
...  
2019 ◽  
Vol 18 (3) ◽  
pp. 41-47
Author(s):  
E. A. Polunina ◽  
L. P. Voronina ◽  
E. A. Popov ◽  
I. S. Belyakova ◽  
O. S. Polunina ◽  
...  

Aim. To develop a mathematical equation (algorithm) to predict the development of chronic heart failure (CHF) for three years, depending on the clinical phenotype.Material and methods. Three hundred forty five patients with CHF with a different left ventricular ejection fraction (preserved, mean, low) were examined. The control group included somatically healthy individuals (n=60). In all patients, 48 parameters that most widely characterize the pathogenesis of CHF (gender-anamnestic, clinical, instrumental, biochemical) were analyzed. To isolate phenotypes, dispersive and cluster analysis was used: the hierarchical classification method and the k-means method. In the development of algorithms we used binary logistic regression method. We used ROC curve to assess the quality of the obtained algorithms.Results. We identified four phenotypes in patients with CHF: fibro-rigid, fibro-inflammatory, inflammatory-destructive, dilated-maladaptive. For the first three phenotypes, a mathematical logistic regression method was used to develop mathematical models for predicting the progression of CHF for three years, with the release of predictors for each phenotype. Belonging to the dilatedmaladaptive phenotype according to the results of the analysis is already an indicator of an unfavorable prognosis in patients with CHF.Conclusion. The developed algorithms based on the selected phenotypes have high diagnostic sensitivity and specificity and can be recommended for use in clinical practice.


2020 ◽  
Vol 6 ◽  
Author(s):  
Davide Margonato ◽  
Simone Mazzetti ◽  
Renata De Maria ◽  
Marco Gorini ◽  
Massimo Iacoviello ◽  
...  

The recent definition of an intermediate clinical phenotype of heart failure (HF) based on an ejection fraction (EF) of between 40% and 49%, namely HF with mid-range EF (HFmrEF), has fuelled investigations into the clinical profile and prognosis of this patient group. HFmrEF shares common clinical features with other HF phenotypes, such as a high prevalence of ischaemic aetiology, as in HF with reduced EF (HFrEF), or hypertension and diabetes, as in HF with preserved EF (HFpEF), and benefits from the cornerstone drugs indicated for HFrEF. Among the HF phenotypes, HFmrEF is characterised by the highest rate of transition to either recovery or worsening of the severe systolic dysfunction profile that is the target of disease-modifying therapies, with opposite prognostic implications. This article focuses on the epidemiology, clinical characteristics and therapeutic approaches for HFmrEF, and discusses the major determinants of transition to HFpEF or HFrEF.


Kardiologiia ◽  
2019 ◽  
Vol 59 (6S) ◽  
pp. 51-60
Author(s):  
V. M. Gazizyanova ◽  
O. V. Bulashova ◽  
E. V. Hazova ◽  
N. R. Hasanov ◽  
V. N. Oslopov

Background. Multimorbidity is a specific characteristic of the modern patient with chronic heart failure (CHF) which significantly changes clinical course, prognosis of the syndrome, leads to socio‑economic losses and makes significant adjustments to treatment tactics. The goal is to study the clinical features and prognosis of patients with CHF in combination with chronic obstructive pulmonary disease (COPD). Materials and methods. We studied 183 HF patients, including with stable CHF, including 105 with CHF combined with COPD. The clinical phenotype was assessed by its belonging to the functional class and the severity of COPD. A 6‑minute walk test (6‑MWT), spirometry, echocardioscopy, testing on a scale assessing the clinical condition, quality of life were studied. The end points during the year were: all‑cause mortality and cardiovascular mortality, myocardial infarction, stroke, pulmonary embolism, and hospitalization rates due to acute decompensation of CHF. Results. The clinical phenotype of CHF combined with COPD was characterized by a high frequency of smoking, low quality of life and exercise tolerance. Respiratory dysfunction in CHF in combination with COPD was characterized by mixed disorders (68.4%), in CHF without lung disease, restrictive (25.6%). Cardiovascular mortality in comorbid pathology was 4.0%, in CHF without COPD – 4.6%; myocardial infarction was observed 1.7 times more often with lung disease than in patients with CHF only (16.8% and 10.8%); stroke was observed exclusively in comorbid pathology (8.9%). The combined endpoint (all cardiovascular events) with CHF in combination with COPD was achieved 2.3 times more often in comparison with patients with COPD only (29.7% and 15.4%). Hospitalization due to acute decompensation of CHF occurred 2 times more often with CHF in combination with COPD than without it (32.7% and 15.4%) with a tendency to increase as the left ventricular ejection fraction decreased. Conclusion. The results of the study demonstrate that COPD contributes to the formation of the clinical phenotype of CHF from the standpoint of the mutual influence of the characteristics of the cardiovascular and respiratory systems, and also aggravates the prognosis that requires an integrated approach to the differential diagnosis and individualization of pharmacotherapy.


2011 ◽  
Vol 57 (14) ◽  
pp. E1266
Author(s):  
David Peter Kao ◽  
Brandie D. Wagner ◽  
Alastair D. Robertson ◽  
John M. Kittelson ◽  
Michael R. Bristow ◽  
...  

2015 ◽  
Author(s):  
Nicholas Wisniewski ◽  
Galyna Bondar ◽  
Christoph Rau ◽  
Jay Chittoor ◽  
Eleanor Chang ◽  
...  

Background The implantation of mechanical circulatory support (MCS) devices in heart failure patients is associated with a systemic inflammatory response, potentially leading to death from multiple organ dysfunction syndrome. Previous studies point to the involvement of many mechanisms, but an integrative hypothesis does not yet exist. Using time-dependent whole-genome mRNA expression in circulating leukocytes, we constructed a systems-model to improve mechanistic understanding and prediction of adverse outcomes. Methods We sampled peripheral blood mononuclear cells from 22 consecutive patients undergoing MCS surgery, at 5 timepoints: day -1 preoperative, and days 1, 3, 5, and 8 postoperative. Phenotyping was performed using 12 clinical parameters, 2 organ dysfunction scoring systems, and survival outcomes. We constructed a systems-representation using weighted gene co-expression network analysis, and annotated eigengenes using gene ontology, pathway, and transcription factor binding site enrichment analyses. Genes and eigengenes were mapped to the clinical phenotype using a linear mixed-effect model, with Cox models also fit at each timepoint to survival outcomes. Finally, we selected top genes associated with survival across all timepoints, and trained a penalized Cox model, based on day -1 data, to predict mortality risk thereafter. Results We inferred a 19-module network, in which most module eigengenes correlated with at least one aspect of the clinical phenotype. We observed a response to surgery orchestrated into stages: first, activation of the innate immune response, followed by anti-inflammation, and finally reparative processes such as mitosis, coagulation, and apoptosis. Eigengenes related to red blood cell production and extracellular matrix degradation became predictors of survival late in the timecourse, consistent with organ failure due to disseminated coagulopathy. Our final predictive model consisted of 10 genes: IL2RA, HSPA7, AFAP1, SYNJ2, LOC653406, GAPDHP35, MGC12916, ZRSR2, and two currently unidentified genes, warranting further investigation. Conclusion Our model provides an integrative representation of leukocyte biology during the systemic inflammatory response following MCS device implantation. It demonstrates consistency with previous hypotheses, identifying a number of known mechanisms. At the same time, it suggests novel hypotheses about time-specific targets.


Author(s):  
Evandro Tinoco Mesquita ◽  
Antonio José Lagoeiro Jorge ◽  
Celso Vale Souza Junior ◽  
Thais Ribeiro de Andrade

Kardiologiia ◽  
2018 ◽  
Vol 58 (12S) ◽  
pp. 4-10 ◽  
Author(s):  
F. T. Ageev ◽  
A. G. Ovchinnikov

The article discusses the clinical expedience of isolating into a separate classification subgroup of patients with heart failure and a mid‑range ejection fraction (EF) of 40–49 %. Analysis of studies 2017–2018 focusing on the issue of patients with mid‑range LV EF showed that this subgroup is highly heterogenous and by some clinical and demographic parameters takes an intermediate position between heart failure (HF) patients with reduced (<40 %) and preserved (>50 %) LV EF. However, patients with mid‑range LV EF positively respond to beta‑blocker and RAAS inhibitor therapy, and their response is close to that of patients with reduced LV EF. This is a principal difference between patients with mid‑range and preserved LV EF who generally do not display any beneficial effect of such therapy. One of the major causes for such difference is a dissimilarity of HF etiology and, hence, pathogenesis in patients with reduced and mid‑range LV EF: primarily IHD (so‑called “ischemic” phenotype) in patients with reduced and mid‑range LV EF and non‑cardiac causes (“non‑ischemic” phenotype) in patients with preserved LV EF. Since the nonischemic phenotype is also rather common among patients with mid‑range LV EF a new HF classification should definitely indicate, in addition to LV EF, the clinical phenotype of disease, which is particularly important for patients with mid‑range LV EF of 40–49 %. Further studies should focus on variants of HF clinical phenotypes.


Sign in / Sign up

Export Citation Format

Share Document